Dr. Tao, Mi-Hua 's orcid link picture Dr. Tao, Mi-Hua 's publons link picture

陶秘華博士

研究員
  • 02-2789-9151 (L) (Lab) (Room No: N229)
  • 02-2652-3078 (O) (Office)
  • 02-2782-9142 (Fax)

Specialty:
  • Viral and Cancer Immunology
  • Viral and Cancer Immunotherapy
  • Vaccine Development
  • Gene Therapy

Education and Positions:
  • Ph.D.  Columbia University (Microbiology and Immunology).

    Postdoctoral Fellow.  Stanford University (Oncology)


  • 日常維護流程─ FACSCelesta
  • 感染性檢體流式細胞儀使用規則(2017)

  • 免疫耐受性常見於慢性病毒感染和癌症病人。我們實驗室的研究主題,主要在闡明存在於慢性B型肝炎病毒感染和腫瘤微環境的免疫耐受機制,並研發治療方法,克服免疫耐受性,重新活化病毒和腫瘤的專一性免疫反應,達到清除B型肝炎病毒和肝癌及其他癌症的目的。在B型肝炎病毒研究方面,我們發展了數種動物模式,包括B型肝炎病毒基因轉殖鼠、攜帶人類肝臟和人類免疫系統的擬人化小鼠、以及類B型肝炎病毒顆粒等。在癌症免疫治療方面,我們發展了原位肝癌、大腸癌肝轉移、和致癌基因引發的原發型乳癌等動物模式來評估治療效果。自新冠病毒大流行爆發以來,我們積極從事COVID-19疫苗的開發,包括mRNA疫苗和重組RBD蛋白疫苗,並將疫苗技術轉移到業界。我們還開發了COVID-19動物攻毒模型,幫助學界和生技公司評估其藥物、抗體或疫苗對SARS-CoV-2 感染的預防或治療效果。

    Our Team
    Team photo

    1. Lu RM, Liang KH, Chiang HL, Hsu FF, Lin HT, Chen WY, Ke FY, Kumari M, Chou YC, Tao MH, Yi-Ling Lin, Wu HC Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. Heliyon 9(5), e15587 (2023) [JCR] [WOS]
    2. Sun CP, Chiu CW, Wu PY, Tsung SI, Lee IJ, Hu CW, Hsu MF, Kuo TJ, Lan YH, Chen LY, Ng HY, Chung MJ, Liao HN, Tseng SC, Lo CH, Chen YJ, Liao CC, Chang CS, Liang JJ, Draczkowski P, Puri S, Chang YC, Huang JS, Chen CC, Kau JH, Chen YH, Liu WC, Wu HC, Danny Hsu ST, Wang IH, Tao MH Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants. MOLECULAR THERAPY 31(11), 3322-3336 (2023) [JCR] [WOS]
    3. Kao CY, Pan YC, Hsiao YH, Lim SK, Cheng TW, Huang SW, Wu SM, Sun CP, Tao MH, Mou KY Improvement of Gene Delivery by Minimal Bacteriophage Particles. ACS nano 17(15), 14532-14544 (2023) [JCR] [WOS]
    4. Sung PS, Sun CP, Tao MH, Hsieh SL Inhibition of SARS-CoV-2-mediated thromboinflammation by CLEC2.Fc. EMBO molecular medicine 15(7), e16351 (2023) [JCR] [WOS]
    5. Huang HC, Wang SH, Fang GC, Chou WC, Liao CC, Sun CP, Jan JT, Ma HH, Ko HY, Ko YA, Chiang MT, Liang JJ, Kuo CT, Lee TA, Morales-Scheihing D, Shen CY, Chen SY, McCullough LD, Cui L, Wernig G, Tao MH, Lin YL, Chang YM, Wang SP, Lai YJ, Li CW Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion. JOURNAL OF MEDICAL VIROLOGY Online ahead of print, Online ahead of print (2023) [JCR] [WOS]
    6. Kumari Monika, Lu Ruei-Min, Li Mu-Chun, Huang Jhih-Liang, Hsu Fu-Fei, Ko Shih-Han, Ke Feng-Yi, Su Shih-Chieh, Liang Kang-Hao, Yuan Joyce Pei-Yi, Chiang Hsiao-Ling, Sun Cheng-Pu, Lee I.-Jung, Li Wen-Shan, Hsieh Hsing-Pang, Tao Mi-Hua, Wu Han-Chung A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies Journal of Biomedical Science 29(1), 68 (2022-9-12) [JCR] [WOS]
    7. Lee IJ, Sun CP, Wu PY, Lan YH, Wang IH, Liu WC, Yuan JP, Chang YW, Tseng SC, Tsung SI, Chou YC, Kumari M, Lin YS, Chen HF, Chen TY, Lin CC, Chiu CW, Hsieh CH, Chuang CY, Cheng CM, Lin HT, Chen WY, Hsu FF, Hong MH, Liao CC, Chang CS, Liang JJ, Ma HH, Chiang MT, Liao HN, Ko HY, Chen LY, Ko YA, Yu PY, Yang TJ, Chiang PC, Hsu ST, Lin YL, Lee CC, Wu HC, Tao MH A booster dose of Delta x Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. Journal of Biomedical Science 29(1), 49 (2022) [JCR] [WOS]
    8. Jung Lee I, Lan YH, Wu PY, Wu YW, Chen YH, Tseng SC, Kuo TJ, Sun CP, Jan JT, Ma HH, Liao CC, Liang JJ, Ko HY, Chang CS, Liu WC, Ko YA, Chen YH, Sie ZL, Tsung SI, Lin YL, Hsuan Wang I, Tao MH A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern. Emerging Microbes & Infections 1-45, 1-45 (2022) [JCR] [WOS]
    9. Hsu FF, Liang KH, Kumari M, Chen WY, Lin HT, Cheng CM, Tao MH, Wu HC An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization. International Journal of Pharmaceutics 627, 122256 (2022) [JCR] [WOS]
    10. Sung PS, Yang SP, Peng YC, Sun CP, Tao MH, Hsieh SL CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation. Journal of Biomedical Science 29(1), 52 (2022) [JCR] [WOS]

    - 博士後研究 -
    member
    孫承溥
    - 研究助理 -
    member
    陳炳梅
    member
    藍玉樺